The Beta Blockers Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Beta Blockers Market:
https://www.thebusinessresearchcompany.com/report/beta-blockers-global-market-report

According to The Business Research Company’s Beta Blockers Global Market Report 2024, The beta blockers market size has grown strongly in recent years. It will grow from $9.16 billion in 2023 to $9.78 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to hypertension management, treatment of cardiovascular diseases, post-myocardial infarction care, migraine prophylaxis, management of anxiety and tremors.

The beta blockers market size is expected to see strong growth in the next few years. It will grow to $12.28 billion in 2028 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to prevalence of cardiovascular diseases, expanded applications in heart failure, combination therapies, focus on hypertension guidelines, exploration of novel indications. Major trends in the forecast period include application in anxiety and performance situations, potential neuroprotective effects, individualized treatment approaches, impact of generic versions, integration with digital health platforms.

The rise in the incidence of cardiovascular diseases is expected to propel the growth of the beta blockers market. Cardiovascular diseases (CVDs) are a group of disorders that affect the heart and blood vessels. The rise in the incidence of cardiovascular diseases is mostly driven by unhealthy diets, poor lifestyles, lack of exercise, tobacco use, and obesity, where beta blockers can help reduce cardiovascular cases by exerting several beneficial effects on the heart and blood vessels. Hence, rising cases of cardiovascular diseases are contributing to the growth of the beta blockers market. For instance, in according to the National health Survey 2020-21 conducted by the Australian Bureau of Statistics, an Australia-based government agency, an estimated 571,000 Australians aged 18 and over (2.9% of the adult population) were living with CHD in 2020-21. Therefore, a rise in the incidence of cardiovascular diseases will fuel the beta blockers market growth.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=10684&type=smp


The beta blockers market covered in this report is segmented –

1) By Type: Non-selective Agents, Selective Agents
2) By Indication: Angina Pectoris, Heart Failure, High Blood Pressure, Other Indications
3) By Drugs: Betaxolol, Acebutolol, Esmolol, Other Drugs
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
5) By Application: Cardiac Diseases, Hypertension, Glaucoma, Other Applications

Product innovation has emerged as a key trend gaining popularity in the beta blockers market. Major market players operating on beta blockers market are concentrating their efforts on creating innovative products to strengthen their position in the market. For instance, in January 2021, Merck, a Germany-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for a medication called VERQUVO (vericiguat). VERQUVO (vericiguat) is a medication indicated for treating heart failure with reduced ejection fraction (HFrEF) in adults. This drug helps to relax and widen blood vessels, reduce strain on the heart, and improve cardiac function.


The beta blockers market report table of contents includes:


1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis

Major Players:

Pfizer Inc.
Novartis AG
Merck & Co. Inc.
AstraZeneca PLC
Johnson and Johnson

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]


Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model